(NASDAQ:NEOT) shares saw light trading volume with 150K shares changing hands on Tuesday. Shares saw a steep decrease in trading volume of 94.03% under the normal average daily volume.
Short traders are feeling a little more bullish on shares of the company lately if you put credence in the motion in short interest. The stock experienced a fall in short interest of -15.34% between September 29, 2017 and October 13, 2017. Short shares fell 88,511 over that timeframe. Days to cover decreased -1.0 to 0.0 and the percentage of shorted shares was 0.04% on October 13.
Here are a few substantial investment firms who have updated their positions. Deutsche Bank Ag grew its investment by buying 37,261 shares an increase of 544.8% from 03/31/2017 to 06/30/2017. Deutsche Bank Ag claims 44,100 shares with a value of $23,000. The value of the position overall is up by 130.0%. As of quarter end Renaissance Technologies LLC had bought 45,400 shares growing its holdings by 424.3%. The value of the company’s investment in Neothetics Cmn went from $17,000 to $30,000 a change of $13,000 quarter over quarter.
As of the end of the quarter Blackrock Inc. had disposed of a total of 3,639 shares trimming its position 69.2%. The value of the investment in NEOT decreased from $8,000 to $1,000 a change of 87.5% for the reporting period. As of quarter end Citadel Advisors LLC had acquired a total of 18,575 shares growing its stake by 131.8%. The value of the investment in (NEOT) went from $23,000 to $18,000 decreasing 21.7% quarter to quarter.
The company is down by 3.20% since yesterday’s close of 1.25. The P/E ratio is N/A and the market value is 16.76M. As of the latest earnings report the EPS was $-0.69 with 13.85M shares outstanding.
Neothetics, Inc., launched on February 1, 2007, is a clinical-stage specialty pharmaceutical company. The Company develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The Company has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is also developing another product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye..